All In Biotech

Drug Trial Radar · NCT07232004

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

A First-in-Human, Phase 1a/b, Single-Dose and Multiple-Dose Study of ABBV-547 to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability in Adult Participants and Efficacy in Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

142

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan. There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 4 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Group 11 is the only group that will receive multiple doses. Approximately 142 adult participants will be enrolled at approximately 21 sites in the United States and Japan. Participants will be administered one dose or multiple doses of ABBV-547 or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Healthy Volunteer
  • Psoriasis

Interventions

  • ABBV-547Drug

    Parental Administration

  • ABBV-547 PlaceboDrug

    Parental Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Day 365

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Total Dermatology /ID# 279798

    Birmingham, Alabama

  • Dermatology Trial Associates /ID# 279984

    Bryant, Arkansas

  • CenExel Act- Anaheim Clinical Trials /ID# 279612

    Anaheim, California

  • Dermatology Research Associates - Los Angeles /ID# 279383

    Los Angeles, California

  • Integrative Skin Science and Research - Location 2 /ID# 279386

    Sacramento, California

  • Wellness Clinical Research - Miami Lakes /ID# 279803

    Miami Lakes, Florida

  • Advanced Clinical Research Institute - Tampa /ID# 279342

    Tampa, Florida

  • Acpru /Id# 278638

    Grayslake, Illinois

  • MetroBoston Clinical Partners /ID# 279992

    Boston, Massachusetts

  • Minnesota Clinical Study Center /ID# 279987

    New Brighton, Minnesota

  • MediSearch Clinical Trials /ID# 279416

    Saint Joseph, Missouri

  • Skin Specialists /ID# 279531

    Omaha, Nebraska

  • The Skin Center Dermatology Group. /ID# 279983

    New City, New York

  • Equity Medical, LLC - Bronx /ID# 279808

    The Bronx, New York

  • Oregon Dermatology and Research Center /ID# 279391

    Portland, Oregon

  • Health Concepts /ID# 279529

    Rapid City, South Dakota

  • Center for Clinical Studies - Houston - Binz Street /ID# 279419

    Houston, Texas

  • Austin Institute for Clinical Research - Pflugerville /ID# 279387

    Pflugerville, Texas

  • Fukuoka University Hospital /ID# 279530

    Fukuoka, Japan

  • University of the Ryukyus Hospital /ID# 279918

    Ginowan-shi, Okinawa, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.